2 ms·
It's very relevant. With the incentives in place now, the most profitable thing a drug company can do is alter an existing drug enough to extend patent protecti
by criddell 10y ago
It's very relevant. With the incentives in place now, the most profitable thing a drug company can do is alter an existing drug enough to extend patent protection for as long as possible. It's sleazy.
Are you not bothered at all about the EpiPen situation? Martin Shkreli doesn't make you angry?
A pharmacologist friend once told me that the best way for a drug company to get a customer for life is to make sure they don't cure or kill them. She was joking, but I think it's true.
- rayiner 10y agoThey can't "extend patent protection" for the drug. Only the improvement. The existing drug loses patent protection. And no, the Epipen thing doesn't bother me. It's narrow minded to think about issues one crisis at a time. The only question is: how do you create a system with the proper incentives? At the end of the day, Mylan runs a very capital intensive business and has a profit margin about half what Google or Apple do. I think it creates perverse and absurd incentives for it to be more profitable to be in the advertising business than to be in the business of saving lives. That's the bottom line.
- criddell 10y ago> They can't "extend patent protection" for the drug Yes they can. The Hatch-Waxman Act was written specifically for this. Also see: http://www.citizen.org/congress/article_redirect.cfm?ID=6435 http://www.citizen.org/congress/article_redirect.cfm?ID=6435 You never said whether or not Martin Shkreli makes you angry. Should investors be encouraged to find undervalued drugs, buy the IP, then raise the price through the roof? That would be good for society? Part of the reason the advertising business is so profitable is due to companies spending so much money on ads. We banned many kinds of cigarette ads because of public health concerns and I would argue that there are legitimate reasons to ban many types of drug ads as well.
- rayiner 10y agoYou're confusing different things. Hatch Waxman does not extend the patent term for orphan drugs. It allows the patent term at the time of FDA approval to be extended to account for unusual approval delays, but only up to the point there is 14 years left post-approval. That has nothing to do with extending the patent term for modifications to the drug, as you state above. As to orphan drugs, Hatch Waxman does not extend patent protection. It provides a period of FDA exclusivity by preventing the filing of a new ANDA application. That provision has nothing to do with Epipen. As for Shkreli--he's an asshole, but it makes no sense to focus narrowly on isolated abuses. Does FDA exclusivity for orphan drugs make up a non-negligible percent of healthcare spending (I think the answer is no)? If not than its just rage-bait, not something that we should base policy judgments on. The big problem here is that manufacturers of generics have almost zero ability to invest in even minimal R&D. So they won't take an out-of-patent drug and use it to treat a long-tail disease. The orphan drug program is limited to diseases affecting less than 200,000 Americans. In the decade before Hatch-Waxmen, only 10 such drugs came to market. Since then, 400 have. So is it reasonable to judge the whole program by the Shkreli example?
- criddell 10y ago> As for Shkreli--he's an asshole, but it makes no sense to focus narrowly on isolated abuses. I take it nobody in your family was affected by the price of a Daraprim tablet going from around $10 to $700 per pill? > The big problem here is that manufacturers of generics have almost zero ability to invest in even minimal R&D. Because that's not what they do. That's like complaining that Belkin makes lightning cables and they aren't even investing in developing new computers.
- rayiner 10y ago> I take it nobody in your family was affected by the price of a Daraprim tablet going from around $10 to $700 per pill? No, but I buy Epipens for my daughter. That fact is, of course, irrelevant. Systems shouldn't be designed by hyper-focusing on corner cases.
- 10y ago